The Central Board of Secondary Education is going to conduct the class 10 Social Science exam on March 7, 2026. With the exam ...

A lady has shared her story as she celebrated graduating with a first-class honours degree in law from the prestigious ...

Identical twins who studied at the University of Ibadan have gone viral as they both finished with a first class from the ...

TRAVEL influencer NonStop Dan is being slammed online after claiming he’s unable to get home from Singapore due to the Iran war, when economy seats were still available on flights. The ...

On days of the board examinations, students should spend the majority of their time on the subject of the next board ...

Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 2026LNCB74 Phase 1 dose escalation trial update planned ...

On March 12, Faith Sisters Bible Study and Fellowship meet at 7 p.m. Visit fccmanhattan.org for more information. Join us for worship in person at 10:45 a.m. Sunday. Rev. Caela Simmons Wood will ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Shivani Mohan from Meerut has achieved All India Rank 71 in the Union Public Service Commission (UPSC) examination, fulfilling her dream of becoming an IAS officer. In the UPSC examination, students ...

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call ...

Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment ...